Stock Scorer

Immucell Corp (ICCC) · Peers

Immucell against the 15 other companies here in its SEC industry, In Vitro & In Vivo Diagnostic Substances. Each figure is the one on the company's own page; the median is the peers', and the rank is among all 16, highest first.

Measure by measure

MeasureICCCPeer medianRank
Market value $97.63M median $380.11M 11 of 16
P/E 25.9× median 23.6× 2 of 4
EV/EBITDA 15.5× median 24.6× 5 of 5
P/S 3.2× median 5.1× 10 of 16
FCF yield 4.3% median -16.5% 2 of 15
Gross margin 40.3% median 55.5% 9 of 12
Operating margin 12.6% median -30.8% 4 of 12
Net margin 12.3% median -38.4% 4 of 12
ROIC 9.8% median -17.6% 4 of 11
ROE 12.0% median -37.1% 4 of 12
Revenue growth (4y, yearly) 9.5% median 10.2% 8 of 15
Current ratio 4.8× median 2.9× 5 of 15
Stock pay / revenue 1.8% median 5.3% 10 of 15
Share count change 10.5% median 6.2% 6 of 15

Green where Immucell is on the better side of the median, red where on the worse; no colour where higher is neither, like size or dividend yield.

The peers, largest first

CompanyMarket valueP/EROICScore
ICCCImmucell Corp $97.63M P/E 25.9× 9.8% 5.9
IDXXIDEXX Laboratories Inc $44.15B P/E 38.7× 57.2% 6.0
LNTHLantheus Holdings, Inc. $6.51B P/E 23.6× 18.5% 6.2
NEOGNeogen Corp $2.58B P/E – -0.6% 4.2
CLDXCelldex Therapeutics, Inc. $2.16B P/E – – 2.9
NTLAIntellia Therapeutics, Inc. $1.60B P/E – -115.4% 3.6
QDELQuidelOrtho Corp $885.31M P/E – -13.8% 3.2
MYGNMyriad Genetics Inc $380.69M P/E – -25.2% 4.7
TKNOAlpha Teknova, Inc. $380.11M P/E – -21.4% 4.1
NNNNAnbio Biotechnology $136.69M P/E 21.3× 25.0% 5.6
IMDXInsight Molecular Diagnostics Inc. $98.50M P/E – – 3.0
AWHLAspira Women's Health Inc. $10.73M P/E – – 4.0
BMRABiomerica Inc $8.49M P/E – -213.5% 3.4
CDIOCardio Diagnostics Holdings, Inc. $5.00M P/E – -68.7% 3.4
QCLSQ/C Technologies, Inc. $4.41M P/E – – 7.5
VNRXVolitionrx Ltd $2.46M P/E – – 4.1

The industry is the Standard Industrial Classification code the company registered with the SEC. It is a broad label: a peer group is a starting point for comparing, not proof that two businesses are alike. None of this is advice.